XBIO: Rega marang dodolan Xenetic Bio

Tandha merek Xenetic Bio (XBIO)

The strong scientific team at Xenetic Biosciences (XBIO) minimizes financial risks, and the P/S market multiple visualizes this stability, where the 1.20 level captures recent values. Cost optimization is based on the full outsourcing of trials to external CROs, while high brand loyalty to XCART supports capitalization. This chart compares actual market demand with the company's revenue.

XBIO (Xenetic Biosciences) riwayat Multiplikator P/S saka 04.07.2022 nganti 17.11.2026

Rincian analitis perusahaan Xenetic Bio (XBIO)

Analisis umum perusahaan:XBIO (xeneticbio.com)
Produk merek Xenetic Biosciences Inc.

Assessing business resilience through the price-to-sales ratio allows an investor to determine the cost per unit of product created. Analyzing the smoothed P/S of Xenetic Biosciences (XBIO) reveals a critical dependence of the valuation on future successes, as the lack of current sales due to the preclinical status of developments renders this indicator extremely volatile and speculative.

Karo sapa Xenetic Biosciences saingan

ONC - Rega marang dodolan|Multiplikator P/S HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Rega marang dodolan|ascentage.com - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CGON (cgoncology.com)|URGN: Multiplikator P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan personalis.com|Kapitalisasi marang pendapatan Erasca Corp (ERAS)|Kapitalisasi marang pendapatan DCTH (Delcath)|Koefisien rega marang pendapatan Y-mAbs Therapeutics, Inc.|Multiplikator P/S AURA (Aura Biosciences Inc)|Rasio kapitalisasi pasar marang pendapatan CADL|ARAY: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Kapitalisasi marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Rasio rega marang pendapatan TuHURA Biosciences Inc.|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|Koefisien rega marang pendapatan Aadi Bioscience|Rasio rega marang pendapatan TScan Therapeutics Inc TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBIT: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CVM (cel-sci.com)|OSTX: Multiplikator P/S|Rega marang dodolan Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan ANL (Adlai Nortye)|Rasio rega marang pendapatan Veru Pharma (VERU)|Multiplikator P/S Tempest Tx (TPST)|Rasio rega marang pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang pendapatan|Mural Oncology - Multiplikator P/S|KAPA - Multiplikator P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan CytoMed|Rasio rega marang pendapatan curis.com|Kapitalisasi marang pendapatan Apollomics, Inc. (APLM)|Multiplikator P/S THAR|Advanced Biomed Corp - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Genprex GNPX|Koefisien rega marang pendapatan Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator P/S|SLRX: Rasio rega marang pendapatan|Purple Biotech (PPBT) - Rasio rega marang pendapatan|AON - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan BGNE|Multiplikator P/S Checkpoint Therapeutics Inc.|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan iCAD ICAD|Multiplikator P/S IKNA (Ikena Oncology, Inc.)|Rasio kapitalisasi pasar marang pendapatan NTBL|Viracta Therapeutics, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Kapitalisasi marang pendapatan|Kapitalisasi marang pendapatan Ascentage Pharma Group Ltd